Document Detail

Potential role of vascular targeted therapy to combat against tumor.
MedLine Citation:
PMID:  19538038     Owner:  NLM     Status:  MEDLINE    
Tumors, like other tissues, have a fundamental requirement for access to the nutrients, oxygen and waste removal functions of the circulatory system. Vascular targeted therapy exploits this basic need, along with molecular heterogeneity observed between normal and tumor blood vessels, to develop efficient and selective chemotherapies that essentially starve tumors by destroying their vasculature. As the basic principle on which this therapy is based differs from agents that directly target cancerous cells, combining it with traditional therapies such as radiation, surgery and existing chemotherapies has the potential to create powerful new anticancer strategies. As the requirement for vascularization is universal to solid tumors, vascular targeted therapies have the potential for broad applicability. Vascular targeted therapies include both angiogenesis inhibitors, which inhibit neovascularization, and vascular disrupting agents, which destroy existing vasculature. Applications of this model include finding peptides that bind specifically to cell surface markers on tumor vessel endothelial cells and might deliver chemotherapeutic agents. Expression profiling with microarrays, serial analysis of gene expression, and in vitro and in vivo screening of phage display libraries have identified candidate peptides for targeted delivery to the tumor endothelium.
Bei Chen; Haifeng Jin; Kaichun Wu
Related Documents :
7022458 - Role of basal lamina in neoplastic disorganization of tissue architecture.
2625178 - Nodular organization and differential intrametastatic distribution of the fluorescent d...
21436588 - Foxo3 programs tumor-associated dcs to become tolerogenic in human and murine prostate ...
2441568 - Structural characterization of neovascularization in adenovirus-12-induced retinal tumor.
18067638 - Immunohistochemical expression of ttf-1 in various cytological subtypes of primary lung...
23706438 - Primary mucinous adenocarcinoma of the posterior mediastinum.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  6     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-25     Completed Date:  2009-09-02     Revised Date:  2009-11-17    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  719-26     Citation Subset:  IM    
The Fourth Military Medical University, Xijing Hospital of Digestive Diseases, State Key Laboratory of Cancer Biology, Xi'an, Shaanxi, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / pharmacology,  therapeutic use*
Antineoplastic Agents / pharmacology,  therapeutic use*
Drug Delivery Systems
Endothelium, Vascular / drug effects
Gene Expression Profiling / methods
Neoplasms / drug therapy*,  genetics,  physiopathology
Neovascularization, Pathologic / drug therapy
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and the...
Next Document:  The use and the user of herbal remedies during pregnancy.